Novel antithrombotic agents for atrial fibrillation

Pharmacology and Therapeutics

Volumn 134, Issue 3, 2012, Pages 345-354

  Niespialowska Steuden, Maria M ^a   Markides, Vias ^b,c   Gorog, Diana A ^a,c,d  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Atrial fibrillation; Direct factor Xa inhibitors; Direct thrombin inhibitors; Novel anticoagulants; Thromboembolism; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATOPAXAR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; LIXIANA; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VORAPAXAR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STROKE; THROMBOEMBOLISM; THROMBOSIS;

ANTITHROMBINS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; RECEPTOR, PAR-1; VITAMIN K;

EID: 84859789405     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.02.006     Document Type: Review

References (67)

1. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 348. (1996)., 633-638.
2. Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., et al. (2011). Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl JMed 365, 699-708.
3. Ansell, J. (2012). New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 125, 165-170 (discussion 170).
4. Baker, W. L., Cios, D. A., Sander, S. D., & Coleman, C. I. (2009). Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15, 244-252.
5. Barrett, Y. C., Wang, Z., Frost, C., & Shenker, A. (2010). Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104, 1263-1271.
6. Bauersachs, R., Berkowitz, S. D., Brenner, B., Buller, H. R., Decousus, H., Gallus, A. S., et al. (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363, 2499-2510.
7. Boehringer Ingelheim Pharmaceuticals, I. (2010). Advisory committee briefing document. (In).
8. Camm, A. J., & Bounameaux, H. (2011). Edoxaban: a new oral direct factor Xa inhibitor. Drugs 71, 1503-1526.
9. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., et al. (2010). Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 12, 1360-1420.
10. Cavallari, L. H., Shin, J., & Perera, M. A. (2011). Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31, 1192-1207.
11. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., et al. (2011). Apixaban in patients with atrial fibrillation. N Engl J Med 364, 806-817.
12. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361, 1139-1151.
13. Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., et al. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912.
14. Deaths from stroke (2004). The atlas of heart disease and stroke. In W. H. Organization(Ed.).
15. Dezee, K. J., Shimeall, W. M., Douglas, K. M., Shumway, N. M., & O'malley, P. G. (2006). Treatment of excessive anticoagulation with phytonadione (vitamin K): A metaanalysis. Arch Intern Med 166(4), 391-397 (Electronic publication ahead of print 2006/03/01).
16. Dietrich, W. D., Dewanjee, S., Prado, R., Watson, B. D., & Dewanjee, M. K. (1993). Transient platelet accumulation in the rat brain after common carotid artery thrombosis. An 111In-labeled platelet study. Stroke 24, 1534-1540.
17. Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011). Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579.
18. Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358, 2765-2775. (Pubitemid 351930851)
19. Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870. (Pubitemid 32537350)
20. Go, A. S., Hylek, E. M., Borowsky, L. H., Phillips, K. A., Selby, J. V., & Singer, D. E. (1999). Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131, 927-934.
21. Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365, 981-992.
22. Granger, C. B., & Armaganijan, L. V. (2012). Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 125, 159-164 (discussion 164).
23. Gruber, A., Marzec, U. M., Buetehorn, U., Hanson, S. R., & Perzborn, E. (2007). Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons. Pathophysiol Haemost Thromb 36(Suppl. 1), A39.
24. Hariharan, S., & Madabushi, R. (2012). Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 52, 119S-125S.
25. Hart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., & Asinger, R. W. (1999). Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke 30, 1223-1229. (Pubitemid 29259178)
26. Heeringa, J., van der Kuip, D. A., Hofman, A., Kors, J. A., van Herpen, G., Stricker, B. H., et al. (2006). Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27, 949-953.
27. Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115, 2689-2696. (Pubitemid 46842784)
28. Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82, 2N-9N. (Pubitemid 28507114)
29. Kazmi, R. S., & Lwaleed, B. A. (2011). New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 72, 593-603.
30. Koh, C. Y., Kumar, S., Kazimirova, M., Nuttall, P. A., Radhakrishnan, U. P., Kim, S., et al. (2011). Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS One 6, e26367.
31. Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358, 2776-2786. (Pubitemid 351930852)
32. Lin, H. J., Wolf, P. A., Kelly-Hayes, M., Beiser, A. S., Kase, C. S., Benjamin, E. J., et al. (1996). Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27, 1760-1764.
33. Lindhoff-Last, E., Samama, M. M., Ortel, T. L., Weitz, J. I., & Spiro, T. E. (2010). Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32, 673-679.
34. Lip, G. Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J. K., Cuisset, T., et al. (2010). Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 31, 1311-1318.
35. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 137, 263-272.
36. Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., et al. (2004). Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042-1046. (Pubitemid 39319000)
37. Majerus, P. W., Broze, G. J., Miletich, J. P., & Tollefsen, D. M. (1996). Anticoagulant thrombolytic, and antiplatelet drugs. In G. a. Gilman's (Ed.), The pharmacological basis of therapeutics (pp. 1347-1351). (9th ed.). New York: McGraw-Hill.
38. Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493-503.
39. Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J. P., Bhatt, D. L., Bode, C., et al. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366, 9-19.
40. O'Donoghue, M. L., Bhatt, D. L., Wiviott, S. D., Goodman, S. G., Fitzgerald, D. J., Angiolillo, D. J., et al. (2011). Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 123, 1843-1853.
41. Ogata, K., Mendell-Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., et al. (2010). Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50, 743-753.
42. Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., et al. (2011). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32, 2781-2789.
43. Patel, M. (2010). Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies. European Stroke Conference Barcelone, Spain.
44. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365, 883-891.
45. Perzborn, E., & Tinel, H. (2007). FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 36(Suppl. 1), A40.
46. Phan, T. T., Ta, T. D., Nguyen, D. T., Van Den Broek, L. A., & Duong, G. T. (2011). Purification and characterization of novel fibrinolytic proteases as potential antithrombotic agents from earthworm Perionyx excavatus. AMB Expr 1, 26.
47. Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., & Lip, G. Y. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138, 1093-1100.
48. Poyarkov, A. A., Poyarkova, S. A., Smirnova, I. V., & Kukhar, V. P. (2012). Liporetro-D-peptides - A novel class of highly selective thrombin inhibitors. Thromb Res 129, e97-e105.
49. Roger, V. L., Go, A. S., Lloyd-Jones, D.M., Adams, R. J., Berry, J. D., Brown, T. M., et al. (2011). Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123, e18-e209.
50. Rosamond, W. D., Folsom, A. R., Chambless, L. E.,Wang, C. H.,McGovern, P. G., Howard, G., et al. (1999). Stroke incidence and survival amongmiddle-aged adults: 9-year followup of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 30, 736-743. (Pubitemid 29156360)
51. Rosenthal, L., Borczuk, P., Chandrakantan, A., Greenberg, M. L., Kocheril, A. G., Lober, W., McManus, D. D., Setnik, G., & Sovari, A. A. (2011). Atrial fibrillation. Medscape.
52. Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., et al. (2010). Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160, 635-641.
53. Samama, M. M., Martinoli, J. L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., et al. (2010). Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 103, 815-825.
54. Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., et al. (2009). Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361, 2342-2352.
55. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342. (1993)., 1255-1262.
56. Stangier, J., Rathgen, K., Stahle, H., Gansser, D., & Roth, W. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64, 292-303. (Pubitemid 47283865)
57. Stollberger, C., Chnupa, P., Abzieher, C., Langer, T., Finsterer, J., Klem, I., et al. (2004). Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol 27, 40-46.
58. Testa, L., Bhindi, R., Agostoni, P., Abbate, A., Zoccai, G. G., & van Gaal, W. J. (2007). The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 6, 397-406. (Pubitemid 351308168)
59. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston area anticoagulation trial for atrial fibrillation investigators. N Engl J Med 323. (1990)., 1505-1511.
60. Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van deWerf, F., et al. (2012). Thrombin-receptor antagonist vorapaxar in Acute Coronary Syndromes. N Eng J Med 366, 20-33.
61. Ustrell, X., & Pellise, A. (2010). Cardiac workup of ischemic stroke. Curr Cardiol Rev 6, 175-183.
62. van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K. H., Wienen, W., Feuring, M., et al. (2010). Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103, 1116-1127.
63. Vorapaxar (2010). Am J Cardiovasc Drugs 10, 413-418.
64. Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., et al. (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376, 975-983.
65. Weinz, C., Schwarz, T., Kubitza, D., Mueck, W., & Lang, D. (2009). Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37, 1056-1064.
66. Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983-988.
67. Wysokinski, W. E., Owen, W. G., Fass, D. N., Patrzalek, D. D., Murphy, L., & McBane, R. D., 2nd (2004). Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost 2, 1637-1644. (Pubitemid 40186182)